10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
8.77
+0.14 (1.62%)
At close: May 9, 2025, 4:00 PM
9.39
+0.62 (7.07%)
Pre-market: May 12, 2025, 8:19 AM EDT
10x Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Revenue | 624.66 | 610.79 | 618.73 | 516.41 | 490.49 | 298.85 | Upgrade
|
| Revenue Growth (YoY) | -0.13% | -1.28% | 19.81% | 5.28% | 64.13% | 21.54% | Upgrade
|
| Cost of Revenue | 197.65 | 196 | 209.41 | 120.09 | 74.09 | 58.47 | Upgrade
|
| Gross Profit | 427.01 | 414.78 | 409.31 | 396.32 | 416.4 | 240.38 | Upgrade
|
| Selling, General & Admin | 348.3 | 343.24 | 343.33 | 295.8 | 257.56 | 202.33 | Upgrade
|
| Research & Development | 260.31 | 264 | 265.73 | 264.27 | 211.75 | 123.38 | Upgrade
|
| Operating Expenses | 608.6 | 607.24 | 609.06 | 560.07 | 469.31 | 325.7 | Upgrade
|
| Operating Income | -181.59 | -192.46 | -199.75 | -163.74 | -52.91 | -85.32 | Upgrade
|
| Interest Expense | -0 | -0 | -0.03 | -0.48 | -0.87 | -1.68 | Upgrade
|
| Interest & Investment Income | 17.4 | 18.45 | 16.91 | 6.65 | 0.21 | 1.53 | Upgrade
|
| Currency Exchange Gain (Loss) | -4.6 | -2.1 | 1.2 | 0.2 | -0.9 | 1.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.19 | 0.52 | 0.21 | -0.4 | 0.1 | 0.04 | Upgrade
|
| EBT Excluding Unusual Items | -162.6 | -175.6 | -181.47 | -157.77 | -54.38 | -84.14 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -4.2 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0 | -0 | -1.72 | - | - | - | Upgrade
|
| Asset Writedown | - | -2.1 | -4.6 | - | - | - | Upgrade
|
| Legal Settlements | 9.2 | - | - | - | 0.66 | -1.27 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -1.52 | Upgrade
|
| Pretax Income | -153.4 | -177.7 | -248.76 | -161.97 | -53.72 | -534.48 | Upgrade
|
| Income Tax Expense | 3.63 | 4.93 | 6.34 | 4.03 | 4.51 | 8.26 | Upgrade
|
| Net Income | -157.04 | -182.63 | -255.1 | -166 | -58.22 | -542.73 | Upgrade
|
| Net Income to Common | -157.04 | -182.63 | -255.1 | -166 | -58.22 | -542.73 | Upgrade
|
| Shares Outstanding (Basic) | 121 | 120 | 117 | 114 | 110 | 101 | Upgrade
|
| Shares Outstanding (Diluted) | 121 | 120 | 117 | 114 | 110 | 101 | Upgrade
|
| Shares Change (YoY) | 2.66% | 2.80% | 2.90% | 3.18% | 9.09% | 158.76% | Upgrade
|
| EPS (Basic) | -1.30 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | Upgrade
|
| EPS (Diluted) | -1.30 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | Upgrade
|
| Free Cash Flow | 45.36 | -5.73 | -63.8 | -165.27 | -122.65 | -254.56 | Upgrade
|
| Free Cash Flow Per Share | 0.37 | -0.05 | -0.55 | -1.45 | -1.11 | -2.52 | Upgrade
|
| Gross Margin | 68.36% | 67.91% | 66.15% | 76.75% | 84.89% | 80.44% | Upgrade
|
| Operating Margin | -29.07% | -31.51% | -32.28% | -31.71% | -10.79% | -28.55% | Upgrade
|
| Profit Margin | -25.14% | -29.90% | -41.23% | -32.15% | -11.87% | -181.61% | Upgrade
|
| Free Cash Flow Margin | 7.26% | -0.94% | -10.31% | -32.00% | -25.01% | -85.18% | Upgrade
|
| EBITDA | -146.88 | -156.58 | -164.24 | -138.38 | -31.8 | -71.31 | Upgrade
|
| EBITDA Margin | -23.51% | -25.64% | -26.54% | -26.80% | -6.48% | -23.86% | Upgrade
|
| D&A For EBITDA | 34.71 | 35.88 | 35.51 | 25.37 | 21.12 | 14.01 | Upgrade
|
| EBIT | -181.59 | -192.46 | -199.75 | -163.74 | -52.91 | -85.32 | Upgrade
|
| EBIT Margin | -29.07% | -31.51% | -32.28% | -31.71% | -10.79% | -28.55% | Upgrade
|
| Advertising Expenses | - | 3.9 | 3.3 | 3.7 | 4.7 | 1.9 | Upgrade
|
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.